Aurora M. Fontainhas

Array ( [id] => 19961629 [patent_doc_number] => 12331113 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-17 [patent_title] => Anti-human NR1 antibody derivative [patent_app_type] => utility [patent_app_number] => 18/981054 [patent_app_country] => US [patent_app_date] => 2024-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 9 [patent_no_of_words] => 37709 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18981054 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19431014 [patent_doc_number] => 20240299512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => IMMUNOTHERAPY COMPOSITIONS AND METHODS FOR TREATMENT OF TAUOPATHY AND TRANSGENIC MOUSE [patent_app_type] => utility [patent_app_number] => 18/636216 [patent_app_country] => US [patent_app_date] => 2024-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11734 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18636216 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19402098 [patent_doc_number] => 20240285609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH [patent_app_type] => utility [patent_app_number] => 18/635980 [patent_app_country] => US [patent_app_date] => 2024-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28992 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18635980 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19387821 [patent_doc_number] => 20240277691 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH [patent_app_type] => utility [patent_app_number] => 18/636026 [patent_app_country] => US [patent_app_date] => 2024-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29000 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18636026 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19402096 [patent_doc_number] => 20240285607 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH [patent_app_type] => utility [patent_app_number] => 18/627162 [patent_app_country] => US [patent_app_date] => 2024-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28998 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18627162 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19402097 [patent_doc_number] => 20240285608 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH [patent_app_type] => utility [patent_app_number] => 18/627244 [patent_app_country] => US [patent_app_date] => 2024-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29007 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18627244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19402095 [patent_doc_number] => 20240285606 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH [patent_app_type] => utility [patent_app_number] => 18/611130 [patent_app_country] => US [patent_app_date] => 2024-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28979 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18611130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19232105 [patent_doc_number] => 20240189296 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH [patent_app_type] => utility [patent_app_number] => 18/437692 [patent_app_country] => US [patent_app_date] => 2024-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29045 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18437692 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19282930 [patent_doc_number] => 20240219406 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => DETECTION OF MISFOLDED ALPHA SYNUCLEIN PROTEIN [patent_app_type] => utility [patent_app_number] => 18/426786 [patent_app_country] => US [patent_app_date] => 2024-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10933 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18426786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19173800 [patent_doc_number] => 20240159774 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => DEFECTIVE CALCIUM SIGNALING AS A TOOL IN AUTISM SPECTRUM DISORDERS [patent_app_type] => utility [patent_app_number] => 18/421058 [patent_app_country] => US [patent_app_date] => 2024-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11678 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18421058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19246861 [patent_doc_number] => 20240197845 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => IMMUNOTHERAPY COMPOSITIONS AND METHODS FOR TREATMENT OF TAUOPATHY AND TRANSGENIC MOUSE [patent_app_type] => utility [patent_app_number] => 18/402899 [patent_app_country] => US [patent_app_date] => 2024-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11717 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18402899 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111164 [patent_doc_number] => 20240122914 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH [patent_app_type] => utility [patent_app_number] => 18/531407 [patent_app_country] => US [patent_app_date] => 2023-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28995 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18531407 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111163 [patent_doc_number] => 20240122913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH [patent_app_type] => utility [patent_app_number] => 18/531052 [patent_app_country] => US [patent_app_date] => 2023-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28984 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18531052 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19002068 [patent_doc_number] => 20240066139 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES [patent_app_type] => utility [patent_app_number] => 18/492894 [patent_app_country] => US [patent_app_date] => 2023-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35457 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18492894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19425287 [patent_doc_number] => 12084690 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-10 [patent_title] => Recombinant hARSA that crosses the blood brain barrier [patent_app_type] => utility [patent_app_number] => 18/488060 [patent_app_country] => US [patent_app_date] => 2023-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 50 [patent_no_of_words] => 12827 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18488060 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19090986 [patent_doc_number] => 11952416 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-09 [patent_title] => Anti-annexin A1 antibodies [patent_app_type] => utility [patent_app_number] => 18/467405 [patent_app_country] => US [patent_app_date] => 2023-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 10171 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18467405 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19112820 [patent_doc_number] => 20240124570 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => INFLAMMASOME ANTIBODY COMPOSITON AND METHOD FOR TREATING NEUROLOGIC DISORDER [patent_app_type] => utility [patent_app_number] => 18/464174 [patent_app_country] => US [patent_app_date] => 2023-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46588 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18464174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879117 [patent_doc_number] => 20240002486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => ANTI-THYMOCYTE GLOBULIN [patent_app_type] => utility [patent_app_number] => 18/456972 [patent_app_country] => US [patent_app_date] => 2023-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11383 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18456972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18971946 [patent_doc_number] => 20240052038 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => Modified anti-PD-L1 Antibody and Methods and Uses for Treating a Neurodegenerative Disease [patent_app_type] => utility [patent_app_number] => 18/360222 [patent_app_country] => US [patent_app_date] => 2023-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79240 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 206 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18360222 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18752371 [patent_doc_number] => 20230355603 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => PSILOCYBIN COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/354403 [patent_app_country] => US [patent_app_date] => 2023-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5482 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18354403 [rel_patent_id] =>[rel_patent_doc_number] =>)